Inês Pires da Silva

5.4k total citations
106 papers, 2.0k citations indexed

About

Inês Pires da Silva is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Inês Pires da Silva has authored 106 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 41 papers in Immunology and 32 papers in Molecular Biology. Recurrent topics in Inês Pires da Silva's work include Cancer Immunotherapy and Biomarkers (45 papers), Immunotherapy and Immune Responses (27 papers) and CAR-T cell therapy research (23 papers). Inês Pires da Silva is often cited by papers focused on Cancer Immunotherapy and Biomarkers (45 papers), Immunotherapy and Immune Responses (27 papers) and CAR-T cell therapy research (23 papers). Inês Pires da Silva collaborates with scholars based in Australia, United States and Portugal. Inês Pires da Silva's co-authors include Georgina V. Long, Iman Osman, Nina Bhardwaj, Anne Gallois, Alexander M. Menzies, Ana C. Anderson, Sonia Jiménez-Baranda, Shaukat Khan, Vijay K. Kuchroo and Matteo S. Carlino and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

Inês Pires da Silva

95 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Inês Pires da Silva Australia 25 1.0k 808 539 247 196 106 2.0k
Keisuke Watanabe Japan 22 1.1k 1.0× 453 0.6× 607 1.1× 214 0.9× 159 0.8× 125 2.2k
Line Bjørge Norway 32 583 0.6× 764 0.9× 633 1.2× 228 0.9× 231 1.2× 138 2.9k
Elísabeth Pérez-Ruiz Spain 20 1.0k 1.0× 600 0.7× 574 1.1× 339 1.4× 302 1.5× 80 1.9k
Andreas Trojan Switzerland 22 741 0.7× 567 0.7× 339 0.6× 295 1.2× 151 0.8× 64 1.8k
Marijo Bilušić United States 22 1.2k 1.1× 889 1.1× 471 0.9× 512 2.1× 173 0.9× 113 2.0k
Yubin Kang United States 24 614 0.6× 459 0.6× 748 1.4× 269 1.1× 162 0.8× 97 1.9k
Abdolrasoul Talei Iran 23 1000 1.0× 614 0.8× 387 0.7× 141 0.6× 341 1.7× 148 1.9k
Young H. Kim United States 29 919 0.9× 898 1.1× 547 1.0× 525 2.1× 222 1.1× 77 2.5k

Countries citing papers authored by Inês Pires da Silva

Since Specialization
Citations

This map shows the geographic impact of Inês Pires da Silva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inês Pires da Silva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inês Pires da Silva more than expected).

Fields of papers citing papers by Inês Pires da Silva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inês Pires da Silva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inês Pires da Silva. The network helps show where Inês Pires da Silva may publish in the future.

Co-authorship network of co-authors of Inês Pires da Silva

This figure shows the co-authorship network connecting the top 25 collaborators of Inês Pires da Silva. A scholar is included among the top collaborators of Inês Pires da Silva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inês Pires da Silva. Inês Pires da Silva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brown, Lauren, Harriet E. Gee, Benjamin Y. Kong, et al.. (2025). Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis. Thoracic Cancer. 16(2). e15510–e15510. 2 indexed citations
2.
Yang, Fengtang, Su Yin Lim, Inês Pires da Silva, et al.. (2025). Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma. Cancer Cell International. 25(1). 424–424.
3.
Silva, Inês Pires da, Lisa Zimmer, Jean‐Yves Blay, et al.. (2025). Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. ESMO Open. 10(11). 105833–105833.
4.
Brown, Lauren, Julie Ahn, Bo Gao, et al.. (2024). Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study. JTO Clinical and Research Reports. 5(10). 100695–100695. 3 indexed citations
5.
Fantoni, A, Lydia Warburton, Benjamin Solomon, et al.. (2024). Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT). Clinical Lung Cancer. 25(5). 449–459.
6.
Joshua, Anthony M., et al.. (2024). An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma. European Journal of Cancer. 214. 115121–115121. 5 indexed citations
7.
Grangeiro, Leílson Costa, et al.. (2024). Early garlic as an alternative for planting in low-altitude regions in the semi-arid region. Chilean journal of agricultural research. 85(1). 123–134.
8.
Gide, Tuba N., Nurudeen A. Adegoke, Camelia Quek, et al.. (2023). Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. Journal of Translational Medicine. 21(1). 257–257. 6 indexed citations
9.
London, Kevin, Alison J. Potter, Serigne Lo, et al.. (2022). Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Research. 32(4). 260–268. 1 indexed citations
10.
Silva, Inês Pires da, Tasnia Ahmed, Florentia Dimitriou, et al.. (2022). Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Journal for ImmunoTherapy of Cancer. 10(7). e004610–e004610. 15 indexed citations
11.
Marsh‐Wakefield, Felix, Robert V. Rawson, Tuba N. Gide, et al.. (2022). Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. JCI Insight. 7(21). 10 indexed citations
12.
Kelly, Greg, Fares Al‐Ejeh, Robert McCuaig, et al.. (2021). G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Clinical Cancer Research. 27(9). 2624–2635. 29 indexed citations
13.
Edwards, Jarem, Annie Tasker, Inês Pires da Silva, et al.. (2019). Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. Clinical Cancer Research. 25(11). 3247–3258. 26 indexed citations
14.
Silva, Inês Pires da, Kevin Wang, James S. Wilmott, et al.. (2019). Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant Melanoma. Clinical Cancer Research. 25(4). 1272–1279. 48 indexed citations
15.
Wang, Kevin, Alexander M. Menzies, Inês Pires da Silva, et al.. (2018). bcGST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. Bioinformatics. 35(8). 1350–1357. 1 indexed citations
16.
Platt, Jeffrey L., Inês Pires da Silva, Samuel J. Balin, et al.. (2017). C3d regulates immune checkpoint blockade and enhances antitumor immunity. JCI Insight. 2(9). 21 indexed citations
17.
Silva, Inês Pires da, Keith M. Giles, Matjaž Vogelsang, et al.. (2015). Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. Clinical Cancer Research. 22(10). 2377–2385. 30 indexed citations
18.
Vogelsang, Matjaž, Inês Pires da Silva, Nathaniel H. Fleming, et al.. (2015). Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. Journal of Medical Genetics. 52(4). 231–239. 17 indexed citations
19.
Silva, Inês Pires da, Anne Gallois, Sonia Jiménez-Baranda, et al.. (2014). Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. Cancer Immunology Research. 2(5). 410–422. 315 indexed citations
20.
Fleming, Nathaniel H., Inês Pires da Silva, Richard L. Shapiro, et al.. (2014). Analysis of Recurrence Patterns in Acral Versus Nonacral Melanoma: Should Histologic Subtype Influence Treatment Guidelines?. Journal of the National Comprehensive Cancer Network. 12(12). 1706–1712. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keisuke Watanabe Breakdown of academic impact, for papers by Line Bjørge Breakdown of academic impact, for papers by Elísabeth Pérez-Ruiz Breakdown of academic impact, for papers by Andreas Trojan Breakdown of academic impact, for papers by Marijo Bilušić Breakdown of academic impact, for papers by Yubin Kang Breakdown of academic impact, for papers by Abdolrasoul Talei Breakdown of academic impact, for papers by Young H. Kim
Rankless by CCL
2026